Elicio Therapeutics, Inc.
No enriched coverage for $ELTX in the last 7 days.
No SEC Form 4 filings for $ELTX in the last 30 days.
See all $ELTX insider activity →Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an a
Elicio Therapeutics (Nasdaq: ELTX) said it closed a $15 million registered direct offering, selling 4,380,313 shares of common stock at gross proceeds of about $15 million. The company will use net proceeds to fund Phase 1 development of ELI-002 7P in metastatic PDAC, pipeline work, and general corporate purposes.
Elicio Therapeutics (NASDAQ:ELTX) shares fell 32.5% after it announced a $15M registered direct offering of 4,380,313 shares. The company plans to use net proceeds, plus existing cash, for Phase 1 development of ELI-002 7P in metastatic pancreatic cancer, pipeline, and working capital. Closure expected around July 6, 2026.
Recent ELTX coverage spans financial news, corporate actions and market movers.
This is a fresh SEC filing tied to quarterly results, but the scraped text does not include the actual financial numbers or guidance details.
The financing reduces near-term cash risk and funds the next clinical step, but the share issuance can pressure the stock via dilution.
Dilutive equity financing to fund Phase 1 development of ELI-002 7P; near-term pressure likely from dilution/overhang into the July 6 close.
The 8-K discloses a new equity financing structure (common stock + pre-funded warrants) that can dilute holders and affect near-term liquidity/financing expectations.
The deal is a near-term funding catalyst but likely dilutive, shifting risk toward execution of the planned Phase 1 and pipeline spend.
AlphAI scores every news story that mentions ELTX with an AI model for sentiment and relevance, and aggregates insider trades from Elicio Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an a
3 min readElicio Therapeutics (Nasdaq: ELTX) said it closed a $15 million registered direct offering, selling 4,380,313 shares of common stock at gross proceeds of about $15 million. The company will use net proceeds to fund Phase 1 development of ELI-002 7P in metastatic PDAC, pipeline work, and general corporate purposes.
4 min readElicio Therapeutics (NASDAQ:ELTX) shares fell 32.5% after it announced a $15M registered direct offering of 4,380,313 shares. The company plans to use net proceeds, plus existing cash, for Phase 1 development of ELI-002 7P in metastatic pancreatic cancer, pipeline, and working capital. Closure expected around July 6, 2026.
4 min readElicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 tm2619637d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 1, 2026, between Elicio Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified
2 min readElicio Therapeutics (Nasdaq: ELTX) priced a $15 million registered direct offering to sell 4,380,313 shares of common stock, expected to close around July 6, 2026. Gross proceeds are about $15M before fees. Net proceeds will fund Phase 1 development of ELI-002 7P in metastatic PDAC and other pipeline/work capital.
3 min readuniQure (QURE) surged 78% after the FDA said the 3-year Phase I/II analysis for AMT-130 in Huntington’s could serve as primary evidence for an accelerated BLA; QURE plans to file in Q3 2026. Elicio (ELTX) rose 71% on Phase 2 AMPLIFY-7P responses. Lunai (LNAI) gained 40% on CEO updates; other biotech movers included CLPT, PLRZ and FTH.
5 min readElicio Therapeutics (ELTX) reported post-hoc results from its Phase 2 AMPLIFY-7P trial of ELI-002 7P in resected mKRAS-driven pancreatic cancer. The study did not meet its primary DFS endpoint in the overall intent-to-treat population, which the company attributed partly to more R1 resections in the ELI-002 arm. In R0 patients (n=121), DFS improved (HR 0.65, p=0.048; median 23.8 vs 12.8 months). Elicio plans a refined Phase 3 focused on R0 patients and additional dosing, and said current cash su
6 min readElicio Therapeutics reported a net loss of $39.6 million and an EPS of $(2.58) for the year ended December 31, 2025, an improvement from 2024. The company's operating loss was $37.7 million, and its cash reserves are projected to fund operations into Q3 2026. Key business highlights include clinical progress for ELI-002 7P in Phase 2, expansion of preclinical programs, and a strategic shift towards off-the-shelf immunotherapies.
3 min readBOSTON, Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- Elicio Therapeutics, Inc. ( Nasdaq: ELTX, "Elicio" or the "Company" ) , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on September 15, 2025, Elicio granted an ...
2 min readBOSTON, Sept. 17, 2025 ( GLOBE NEWSWIRE ) -- Elicio Therapeutics, Inc. ( Nasdaq: ELTX, "Elicio" or the "Company" ) , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced immunogenicity testing data showing that ...
3 min read
